# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

> **NCT05900531** · PHASE1 · COMPLETED · sponsor: **Kallyope Inc.** · enrollment: 60 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** K-757
- **DRUG:** K-757 and open-label sitagliptin
- **DRUG:** Matching placebo to K-757
- **DRUG:** Matching placebo to K-757 and matching placebo to K-833
- **DRUG:** K-757 and K-833
- **DRUG:** Matching placebo to K-757, open-label sitagliptin

## Key facts

- **NCT ID:** NCT05900531
- **Lead sponsor:** Kallyope Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-21
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900531, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05900531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*